Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,070.00 at Sanford C. Bernstein

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective reduced by analysts at Sanford C. Bernstein from $1,110.00 to $1,070.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s price objective would suggest a potential upside of 47.36% from the stock’s current price.

REGN has been the subject of a number of other reports. Leerink Partners reiterated a “market perform” rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Oppenheimer reduced their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Bank of America reaffirmed an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,050.29.

Regeneron Pharmaceuticals Trading Up 1.4 %

NASDAQ REGN traded up $9.83 on Tuesday, reaching $726.09. The company had a trading volume of 194,508 shares, compared to its average volume of 510,673. The business has a 50 day moving average of $764.19 and a two-hundred day moving average of $970.66. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market cap of $79.79 billion, a price-to-earnings ratio of 17.97, a P/E/G ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals has a fifty-two week low of $693.00 and a fifty-two week high of $1,211.20.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in REGN. Diversified Trust Co lifted its holdings in shares of Regeneron Pharmaceuticals by 93.0% during the 4th quarter. Diversified Trust Co now owns 2,330 shares of the biopharmaceutical company’s stock worth $1,660,000 after acquiring an additional 1,123 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Regeneron Pharmaceuticals by 23.6% in the 4th quarter. Nordea Investment Management AB now owns 42,667 shares of the biopharmaceutical company’s stock worth $30,160,000 after purchasing an additional 8,135 shares in the last quarter. RK Asset Management LLC increased its position in shares of Regeneron Pharmaceuticals by 9.9% during the 4th quarter. RK Asset Management LLC now owns 9,989 shares of the biopharmaceutical company’s stock valued at $7,115,000 after purchasing an additional 896 shares during the last quarter. Everence Capital Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 2.4% in the 4th quarter. Everence Capital Management Inc. now owns 3,831 shares of the biopharmaceutical company’s stock worth $2,729,000 after acquiring an additional 90 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.